Viewing Study NCT03214666

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:35 PM
Ignite Modification Date: 2026-02-21 @ 6:24 AM
Study NCT ID: NCT03214666
Status: TERMINATED
Last Update Posted: 2022-11-10
First Post: 2017-07-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Sponsor: GT Biopharma, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None High-risk Myelodysplastic Syndromes View
None Acute Myelogenous Leukemia View
None Systemic Mastocytosis View
None Mast Cell Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelodysplastic Syndromes (MDS) View
None Acute Myeloid Leukemia (AML) View